• Explore /
  • Poster
  • / Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.

Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.

Abstract Video & Slides Poster

Authors

Aditya Bardia

Aditya Bardia

Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

Aditya Bardia , Sara M. Tolaney , Delphine Loirat , Kevin Punie , Mafalda Oliveira , Hope S. Rugo , Adam Brufsky , Kevin Kalinsky , Javier Cortes , Joyce O'Shaughnessy , Veronique C Dieras , Lisa A. Carey , Luca Gianni , Martine J. Piccart-Gebhart , Sibylle Loibl , Yanni Zhu , See-Chun Phan , Sara A. Hurvitz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Triple-Negative

Clinical Trial Registration Number

NCT02574455

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 1071)

DOI

10.1200/JCO.2022.40.16_suppl.1071

Abstract #

1071

Poster Bd #

449

Abstract Disclosures

Similar Posters

First Author: Lisa A. Carey

First Author: Joyce O'Shaughnessy

First Author: Eric P. Winer

First Author: Hope S. Rugo